







an Open Access Journal by MDPI

Systems Biology of Tumor Immune Microenvironment and Immuno-Oncology

Guest Editors:

Dr. Wei Wei

1. Assistant Professor, Institute for Systems Biology, Seattle, WA, USA

2. Adj. Assistant Professor, UCLA Pharmacology, Los Angeles, CA, USA

Dr. Vésteinn Thórsson

Institute for Systems Biology, Seattle, WA, USA

Dr. Yin Tang

Institute for Systems Biology, Seattle, WA, USA

Deadline for manuscript submissions:

closed (30 June 2023)

Message from the Guest Editors

Dear Colleagues,

The intricate ecosystem of the tumor immune microenvironment (TIME) is critical to tumor progression and anti-tumor therapy responses. In the last decade, cancer immunotherapies have caused a paradigm shift in cancer treatment and have greatly improved patient clinical outcomes for multiple cancer types. The advancements in our understanding of the TIME have led to the identification of multiple critical components that are essential for eliciting a successful anti-tumor immune Notably. immunosuppressive response. the microenvironment impairs the anti-tumor immune response and needs to be investigated extensively and targeted therapeutically.

In this Special Issue, original research articles and reviews are welcome. We look forward to receiving your contributions.

Dr. Wei Wei

Dr. Vésteinn Thórsson

Dr. Yin Tang *Guest Editors*













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us